99 related articles for article (PubMed ID: 22026922)
1. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.
Giovannetti E; Pacetti P; Reni M; Leon LG; Mambrini A; Vasile E; Ghidini M; Funel N; Lucchesi M; Cereda S; Peters GJ; Cantore M
Pharmacogenomics; 2011 Dec; 12(12):1641-52. PubMed ID: 22026922
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back.
Avan A; Pacetti P; Reni M; Milella M; Vasile E; Mambrini A; Vaccaro V; Caponi S; Cereda S; Peters GJ; Cantore M; Giovannetti E
Int J Cancer; 2013 Aug; 133(4):1016-22. PubMed ID: 23390054
[TBL] [Abstract][Full Text] [Related]
3. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
[TBL] [Abstract][Full Text] [Related]
5. Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine.
Pacetti P; Giovannetti E; Mambrini A; Nannizzi S; Orlandi M; Tartarini R; Del Freo A; Del Tacca M; Danesi R; Cantore M
Anticancer Res; 2009 May; 29(5):1835-40. PubMed ID: 19443413
[TBL] [Abstract][Full Text] [Related]
6. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy.
Sakano S; Wada T; Matsumoto H; Sugiyama S; Inoue R; Eguchi S; Ito H; Ohmi C; Matsuyama H; Naito K
Br J Cancer; 2006 Sep; 95(5):561-70. PubMed ID: 16880786
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
8. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
Font A; Salazar R; Maurel J; Taron M; Ramirez JL; Tabernero J; Gallego R; Casado E; Manzano JL; Carcereny E; Guix M; Fernández-Llamazares J; Rosell R
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1075-83. PubMed ID: 18335219
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
Iranzo V; Sirera R; Bremnes RM; Blasco A; Jantus-Lewintre E; Tarón M; Berrocal A; Blasco S; Caballero C; Del Pozo N; Rosell R; Camps C
Clin Lung Cancer; 2011 Jul; 12(4):224-30. PubMed ID: 21726821
[TBL] [Abstract][Full Text] [Related]
11. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.
Li P; Wang YD; Cheng J; Chen JC; Ha MW
Tumour Biol; 2015 Dec; 36(12):9465-73. PubMed ID: 26124006
[TBL] [Abstract][Full Text] [Related]
12. Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
Cheng H; Qin Q; Sun X; Li F; Sun N; Cheng L; Lu Z; Chen B
Technol Cancer Res Treat; 2013 Oct; 12(5):473-82. PubMed ID: 23617284
[TBL] [Abstract][Full Text] [Related]
13. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
[TBL] [Abstract][Full Text] [Related]
14. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
[TBL] [Abstract][Full Text] [Related]
15. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.
Lamas MJ; Duran G; Balboa E; Bernardez B; Touris M; Vidal Y; Gallardo E; Lopez R; Carracedo A; Barros F
Pharmacogenomics; 2011 Mar; 12(3):433-42. PubMed ID: 21449681
[TBL] [Abstract][Full Text] [Related]
16. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY
Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663
[TBL] [Abstract][Full Text] [Related]
17. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
18. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of northern Spain.
López-Cima MF; González-Arriaga P; García-Castro L; Pascual T; Marrón MG; Puente XS; Tardón A
BMC Cancer; 2007 Aug; 7():162. PubMed ID: 17705814
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
